Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field
Prasad S. Kulkarni, Julia L. Hurwitz, Eric A. F. Simões, et al.
Viral Immunology (2018) Vol. 31, Iss. 2, pp. 195-203
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Lisa A. Jackson, Evan J. Anderson, Nadine Rouphael, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 20, pp. 1920-1931
Open Access | Times Cited: 3209
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Dami A. Collier, Anna De Marco, Isabella A. T. M. Ferreira, et al.
Nature (2021) Vol. 593, Iss. 7857, pp. 136-141
Open Access | Times Cited: 691
Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine
Raul Pellini, Aldo Venuti, Fulvia Pimpinelli, et al.
EClinicalMedicine (2021) Vol. 36, pp. 100928-100928
Open Access | Times Cited: 179
SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies
Dami A. Collier, Anna De Marco, Isabella A. T. M. Ferreira, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 166
Recent updates on correlates of vaccine-induced protection
Stanley A. Plotkin
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 42
Updates on immunologic correlates of vaccine-induced protection
Stanley A. Plotkin
Vaccine (2019) Vol. 38, Iss. 9, pp. 2250-2257
Closed Access | Times Cited: 139
Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants
Eric A. F. Simões, Eduardo Forleo‐Neto, Gregory P. Geba, et al.
Clinical Infectious Diseases (2020) Vol. 73, Iss. 11, pp. e4400-e4408
Open Access | Times Cited: 111
B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV
Johannes F. Scheid, Christopher O. Barnes, Basak Eraslan, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3205-3221.e24
Open Access | Times Cited: 88
Immunopathology of RSV: An Updated Review
Harrison C. Bergeron, Ralph A. Tripp
Viruses (2021) Vol. 13, Iss. 12, pp. 2478-2478
Open Access | Times Cited: 65
OBESITY MAY HAMPER SARS-CoV-2 VACCINE IMMUNOGENICITY
Raul Pellini, Aldo Venuti, Fulvia Pimpinelli, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 61
Decline of RSV-specific antibodies during the COVID-19 pandemic
Gerco den Hartog, Puck B. van Kasteren, Rutger M. Schepp, et al.
The Lancet Infectious Diseases (2022) Vol. 23, Iss. 1, pp. 23-25
Open Access | Times Cited: 54
RSV disease in infants and young children: Can we see a brighter future?
Eugenio Baraldi, Giovanni Checcucci Lisi, Claudio Costantino, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 4
Open Access | Times Cited: 48
Antibody effector functions are associated with protection from respiratory syncytial virus
Yannic C. Bartsch, Deniz Cizmeci, Jaewon Kang, et al.
Cell (2022) Vol. 185, Iss. 26, pp. 4873-4886.e10
Open Access | Times Cited: 38
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers
Flaminia Campo, Aldo Venuti, Fulvia Pimpinelli, et al.
Vaccines (2021) Vol. 9, Iss. 10, pp. 1125-1125
Open Access | Times Cited: 42
Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
Tyler Brady, Corinne Cayatte, Tiffany Barnes, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
State of the Art and Emerging Technologies in Vaccine Design for Respiratory Pathogens
Matteo Ridelfi, Giulio Pierleoni, V. Fonseca, et al.
Seminars in Respiratory and Critical Care Medicine (2025)
Closed Access
A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults
Antonios O. Aliprantis, Dennis Wolford, Luzelena Caro, et al.
Clinical Pharmacology in Drug Development (2020) Vol. 10, Iss. 5, pp. 556-566
Closed Access | Times Cited: 43
Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution
Vincenzo Di Noia, Fulvia Pimpinelli, Davide Renna, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 24, pp. 6815-6823
Open Access | Times Cited: 37
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis
Brian M. Maas, Jos Lommerse, Nele Plock, et al.
EBioMedicine (2021) Vol. 73, pp. 103651-103651
Open Access | Times Cited: 36
SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies
Ravindra K. Gupta, Dami A. Collier, Anna De Marco, et al.
Research Square (Research Square) (2021)
Open Access | Times Cited: 28
Epitope-Specific Serological Assays for RSV: Conformation Matters
Emily Phung, Lauren A. Chang, Kaitlyn M. Morabito, et al.
Vaccines (2019) Vol. 7, Iss. 1, pp. 23-23
Open Access | Times Cited: 34
Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection
Nita Patel, Mike Massare, Jing-Hui Tian, et al.
Vaccine (2019) Vol. 37, Iss. 41, pp. 6112-6124
Open Access | Times Cited: 31
Value profile for respiratory syncytial virus vaccines and monoclonal antibodies
Jessica A. Fleming, Ranju Baral, Deborah Higgins, et al.
Vaccine (2023) Vol. 41, pp. S7-S40
Open Access | Times Cited: 9
Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models
Eiríkur Saeland, Leslie van der Fits, Renske Bolder, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 8
Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19
Merve Kalkan-Yazıcı, Meliha Meric Koç, Nesibe Selma Çetin, et al.
The Journal of Immunology (2020) Vol. 205, Iss. 10, pp. 2719-2725
Closed Access | Times Cited: 23
Page 1 - Next Page

Scroll to top